NASDAQ:ALXNAlexion Pharmaceuticals Stock Price, Forecast & News

Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALXN shares have increased by 32.7% and is now trading at $111.13. View which stocks have been most impacted by Coronavirus.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings, 16 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alexion Pharmaceuticals.

Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Alexion Pharmaceuticals.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported $3.22 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.71 by $0.51. The biopharmaceutical company had revenue of $1.44 billion for the quarter, compared to analysts' expectations of $1.36 billion. Alexion Pharmaceuticals had a return on equity of 21.96% and a net margin of 44.83%. Alexion Pharmaceuticals's quarterly revenue was up 26.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.39 earnings per share. View Alexion Pharmaceuticals' earnings history.

Alexion Pharmaceuticals updated its FY20 earnings guidance on Wednesday, May, 6th. The company provided EPS guidance of $10.45-$10.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.96. The company issued revenue guidance of $5.23-$5.33 billion, compared to the consensus revenue estimate of $5.51 billion.

24 Wall Street analysts have issued 1-year target prices for Alexion Pharmaceuticals' shares. Their forecasts range from $110.00 to $180.00. On average, they anticipate Alexion Pharmaceuticals' share price to reach $143.95 in the next twelve months. This suggests a possible upside of 29.5% from the stock's current price. View analysts' price targets for Alexion Pharmaceuticals.

Headlines about ALXN stock have trended extremely negative recently, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alexion Pharmaceuticals earned a news sentiment score of -4.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the next few days. View the latest news about Alexion Pharmaceuticals.

Alexion Pharmaceuticals saw a decline in short interest in June. As of June 15th, there was short interest totaling 4,500,000 shares, a decline of 5.3% from the May 31st total of 4,750,000 shares. Based on an average daily volume of 2,620,000 shares, the short-interest ratio is currently 1.7 days. Approximately 2.1% of the company's shares are sold short. View Alexion Pharmaceuticals' Current Options Chain.

Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Alibaba Group (BABA), Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Micron Technology (MU), Celgene (CELG), AbbVie (ABBV), Walt Disney (DIS), Visa (V) and Biogen (BIIB).

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include DNB Asset Management AS (0.34%), Factory Mutual Insurance Co. (0.33%), Envestnet Asset Management Inc. (0.11%), Vigilant Capital Management LLC (0.04%), International Biotechnology Trust PLC (0.04%) and State of Alaska Department of Revenue (0.03%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Ludwig Hantson. View institutional ownership trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Factory Mutual Insurance Co., IFM Investors Pty Ltd, First Citizens Bank & Trust Co., Exane Derivatives, Gateway Investment Advisers LLC, CNB Bank, and CENTRAL TRUST Co. View insider buying and selling activity for Alexion Pharmaceuticals.

ALXN stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., State of Alaska Department of Revenue, Cullinan Associates Inc., International Biotechnology Trust PLC, TrimTabs Asset Management LLC, BKD Wealth Advisors LLC, Contravisory Investment Management Inc., and Sanders Morris Harris LLC. View insider buying and selling activity for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $111.13.

Alexion Pharmaceuticals has a market capitalization of $24.54 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. Alexion Pharmaceuticals employs 3,082 workers across the globe.

The official website for Alexion Pharmaceuticals is www.alexion.com.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]